|
Oncology
In 2001 Genentech realized more than $1 billion
in revenues from marketed oncology products, and we
are focused on becoming the industry leader in cancer
therapies. Nine projects in our pipeline are aimed
at various cancers, including breast, colon, lung
and pancreatic, plus non-Hodgkin’s lymphoma,
other hematologic malignancies and solid tumor cancers.
Cardiovascular
Disease
Genentech’s pipeline has one potential product
and one potential new indication for an already marketed
product in the cardiovascular category. From our established
position in the thrombolytic field, we are branching
out to address such significant disease conditions
as acute coronary syndrome.
Immunological
Disease
Genentech’s rapidly growing expertise in immunology
is represented in all three clinical trial phases,
with projects targeting disease states affecting circulation,
respiration, joints, the skin and transplant rejection.
Two of the most advanced projects in our pipeline,
Xolair for adult allergic asthma and Xanelim for moderate-to-severe
psoriasis, are aimed at immunological conditions.
Other
Unmet Needs
Genentech considers other interesting projects that
fall outside these three therapeutic focus areas,
provided they utilize the company’s significant
expertise and address medical needs in areas where
few effective therapies exist. Two such projects are
moving through the development pipeline, including
a potential new indication for use of Nutropin Depot
in adults with growth hormone deficiency. The product
is already approved and marketed for use with children
who are deficient in growth hormone.
|
